Additionally, xenograft experiments conducted by Wang et al (110) identified that IFN-α and sorafenib combination therapy on exhibited an enhanced effect on tumor growth inhibition and apoptosis induction in vivo, providing rationale for the clinical application of IFN-α and sorafenib combination therapy in HCC treatment, which may be use in clinical practice in the near future. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.